JP2004529908A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004529908A5 JP2004529908A5 JP2002573030A JP2002573030A JP2004529908A5 JP 2004529908 A5 JP2004529908 A5 JP 2004529908A5 JP 2002573030 A JP2002573030 A JP 2002573030A JP 2002573030 A JP2002573030 A JP 2002573030A JP 2004529908 A5 JP2004529908 A5 JP 2004529908A5
- Authority
- JP
- Japan
- Prior art keywords
- ntp
- use according
- group
- disease
- gland
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000024891 symptom Diseases 0.000 claims 26
- 210000002784 stomach Anatomy 0.000 claims 20
- 210000001519 tissue Anatomy 0.000 claims 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 18
- 210000004027 cell Anatomy 0.000 claims 17
- 239000000203 mixture Substances 0.000 claims 17
- 206010028980 Neoplasm Diseases 0.000 claims 16
- 201000010099 disease Diseases 0.000 claims 15
- 210000000481 breast Anatomy 0.000 claims 12
- 210000002808 connective tissue Anatomy 0.000 claims 12
- 210000001508 eye Anatomy 0.000 claims 12
- 229920002521 macromolecule Polymers 0.000 claims 12
- 210000000214 mouth Anatomy 0.000 claims 12
- 210000003205 muscle Anatomy 0.000 claims 12
- 210000001331 nose Anatomy 0.000 claims 12
- 210000002741 palatine tonsil Anatomy 0.000 claims 12
- 210000003800 pharynx Anatomy 0.000 claims 12
- 108090000623 proteins and genes Proteins 0.000 claims 12
- 210000002307 prostate Anatomy 0.000 claims 11
- 102000004169 proteins and genes Human genes 0.000 claims 11
- 206010062767 Hypophysitis Diseases 0.000 claims 10
- 210000004100 adrenal gland Anatomy 0.000 claims 10
- 210000004369 blood Anatomy 0.000 claims 10
- 239000008280 blood Substances 0.000 claims 10
- 210000000988 bone and bone Anatomy 0.000 claims 10
- 210000004556 brain Anatomy 0.000 claims 10
- 210000001072 colon Anatomy 0.000 claims 10
- 210000003238 esophagus Anatomy 0.000 claims 10
- 210000000232 gallbladder Anatomy 0.000 claims 10
- 210000004392 genitalia Anatomy 0.000 claims 10
- 210000002216 heart Anatomy 0.000 claims 10
- 210000000936 intestine Anatomy 0.000 claims 10
- 210000003734 kidney Anatomy 0.000 claims 10
- 210000004185 liver Anatomy 0.000 claims 10
- 210000004072 lung Anatomy 0.000 claims 10
- 210000001165 lymph node Anatomy 0.000 claims 10
- 210000001672 ovary Anatomy 0.000 claims 10
- 210000000496 pancreas Anatomy 0.000 claims 10
- 210000003635 pituitary gland Anatomy 0.000 claims 10
- 210000000664 rectum Anatomy 0.000 claims 10
- 210000003079 salivary gland Anatomy 0.000 claims 10
- 210000003491 skin Anatomy 0.000 claims 10
- 210000000952 spleen Anatomy 0.000 claims 10
- 210000001550 testis Anatomy 0.000 claims 10
- 210000001685 thyroid gland Anatomy 0.000 claims 10
- 210000003932 urinary bladder Anatomy 0.000 claims 10
- 210000004291 uterus Anatomy 0.000 claims 10
- 210000005069 ears Anatomy 0.000 claims 9
- 238000012986 modification Methods 0.000 claims 9
- 230000004048 modification Effects 0.000 claims 9
- 210000002990 parathyroid gland Anatomy 0.000 claims 9
- 230000005855 radiation Effects 0.000 claims 9
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 7
- 208000026350 Inborn Genetic disease Diseases 0.000 claims 6
- 230000006378 damage Effects 0.000 claims 6
- 231100000572 poisoning Toxicity 0.000 claims 6
- 230000000607 poisoning effect Effects 0.000 claims 6
- 102000004190 Enzymes Human genes 0.000 claims 5
- 108090000790 Enzymes Proteins 0.000 claims 5
- 206010020880 Hypertrophy Diseases 0.000 claims 5
- 230000036244 malformation Effects 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 238000002647 laser therapy Methods 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 208000019553 vascular disease Diseases 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical class C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 claims 3
- 208000035473 Communicable disease Diseases 0.000 claims 3
- 208000027205 Congenital disease Diseases 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 3
- 208000027219 Deficiency disease Diseases 0.000 claims 3
- 206010016654 Fibrosis Diseases 0.000 claims 3
- 208000028782 Hereditary disease Diseases 0.000 claims 3
- 208000024556 Mendelian disease Diseases 0.000 claims 3
- 208000027418 Wounds and injury Diseases 0.000 claims 3
- 238000009825 accumulation Methods 0.000 claims 3
- 206010002022 amyloidosis Diseases 0.000 claims 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 230000006907 apoptotic process Effects 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000002537 cosmetic Substances 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 239000000412 dendrimer Substances 0.000 claims 3
- 229920000736 dendritic polymer Polymers 0.000 claims 3
- 208000016097 disease of metabolism Diseases 0.000 claims 3
- 208000030172 endocrine system disease Diseases 0.000 claims 3
- 230000007613 environmental effect Effects 0.000 claims 3
- 206010015037 epilepsy Diseases 0.000 claims 3
- 230000004761 fibrosis Effects 0.000 claims 3
- 229910003472 fullerene Inorganic materials 0.000 claims 3
- 208000016361 genetic disease Diseases 0.000 claims 3
- 239000003102 growth factor Substances 0.000 claims 3
- 206010020718 hyperplasia Diseases 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 208000014674 injury Diseases 0.000 claims 3
- 208000030159 metabolic disease Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 230000001537 neural effect Effects 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 208000015380 nutritional deficiency disease Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 238000002054 transplantation Methods 0.000 claims 3
- 230000000472 traumatic effect Effects 0.000 claims 3
- 108010032375 AD7c-NTP Proteins 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 108010014691 Lithostathine Proteins 0.000 claims 2
- 102000016997 Lithostathine Human genes 0.000 claims 2
- 108091005804 Peptidases Proteins 0.000 claims 2
- 239000004365 Protease Substances 0.000 claims 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- 210000000577 adipose tissue Anatomy 0.000 claims 2
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 229940088710 antibiotic agent Drugs 0.000 claims 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 238000000315 cryotherapy Methods 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000005670 electromagnetic radiation Effects 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 238000001415 gene therapy Methods 0.000 claims 2
- 210000004209 hair Anatomy 0.000 claims 2
- 238000010438 heat treatment Methods 0.000 claims 2
- 229940127121 immunoconjugate Drugs 0.000 claims 2
- 238000009169 immunotherapy Methods 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 238000001361 intraarterial administration Methods 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 238000007912 intraperitoneal administration Methods 0.000 claims 2
- 238000007913 intrathecal administration Methods 0.000 claims 2
- 230000002601 intratumoral effect Effects 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 238000007914 intraventricular administration Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 244000045947 parasite Species 0.000 claims 2
- 239000000816 peptidomimetic Substances 0.000 claims 2
- 230000002186 photoactivation Effects 0.000 claims 2
- 238000001126 phototherapy Methods 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 238000002255 vaccination Methods 0.000 claims 2
- 210000003462 vein Anatomy 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 206010051482 Prostatomegaly Diseases 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 239000000411 inducer Substances 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 230000000849 parathyroid Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27395701P | 2001-03-08 | 2001-03-08 | |
| PCT/IB2002/001959 WO2002074323A2 (en) | 2001-03-08 | 2002-03-08 | Using neural thread proteins to treat tumors and other hyperproliferative disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004529908A JP2004529908A (ja) | 2004-09-30 |
| JP2004529908A5 true JP2004529908A5 (enExample) | 2005-12-22 |
Family
ID=23046145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002573030A Pending JP2004529908A (ja) | 2001-03-08 | 2002-03-08 | 細胞の除去または破壊を必要とする、腫瘍および他の症状を治療するための神経糸タンパク質の使用方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20030054990A1 (enExample) |
| EP (2) | EP1368054B1 (enExample) |
| JP (1) | JP2004529908A (enExample) |
| KR (1) | KR100632903B1 (enExample) |
| CN (1) | CN1529613A (enExample) |
| AT (1) | ATE374619T1 (enExample) |
| AU (1) | AU2002304314B2 (enExample) |
| BR (1) | BR0207638A (enExample) |
| CA (1) | CA2439757A1 (enExample) |
| CY (1) | CY1109650T1 (enExample) |
| DE (1) | DE60222745T2 (enExample) |
| DK (1) | DK1368054T3 (enExample) |
| ES (1) | ES2295347T3 (enExample) |
| PT (1) | PT1368054E (enExample) |
| WO (1) | WO2002074323A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002308327B2 (en) * | 2001-05-04 | 2006-11-30 | Nymox Corporation | Method of preventing cell death using antibodies to neural thread proteins |
| EP1541166B1 (en) * | 2001-05-16 | 2007-12-19 | Nymox Corporation | Preventing cell death using segments of neural thread proteins |
| DE60205366T2 (de) * | 2001-05-16 | 2006-05-24 | Nymox Corp., Saint-Laurent | Prävention des zelltodes durch verwendung der segmente der neurofilamentproteine |
| WO2002097030A2 (en) * | 2001-05-25 | 2002-12-05 | Nymox Corporation | Peptides derived from neural thread proteins and their medical use |
| US7544771B2 (en) * | 2005-02-23 | 2009-06-09 | Nymox Corporation | Protein and its use in diagnosing Alzheimer's disease |
| US8211450B2 (en) | 2010-05-05 | 2012-07-03 | Senju Usa, Inc. | Ophthalmic composition |
| WO2011159829A2 (en) * | 2010-06-15 | 2011-12-22 | Old Dominion University Research Foundation | Method and device for treatment of conditions aggravated by amyloid fibrils |
| US9642687B2 (en) | 2010-06-15 | 2017-05-09 | The Procter & Gamble Company | Methods for whitening teeth |
| US20160361380A1 (en) | 2015-06-12 | 2016-12-15 | Nymox Corporation | Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations |
| US11628202B2 (en) | 2015-07-24 | 2023-04-18 | Nymox Corporation | Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia |
| US10183058B2 (en) | 2016-06-17 | 2019-01-22 | Nymox Corporation | Method of preventing or reducing the progression of prostate cancer |
| US10172910B2 (en) | 2016-07-28 | 2019-01-08 | Nymox Corporation | Method of preventing or reducing the incidence of acute urinary retention |
| US10532081B2 (en) | 2016-09-07 | 2020-01-14 | Nymox Corporation | Method of ameliorating or preventing the worsening or the progression of symptoms of BPH |
| US10335453B2 (en) | 2017-03-01 | 2019-07-02 | Nymox Corporation | Compositions and methods for improving sexual function |
| CN108341854B (zh) * | 2018-02-09 | 2020-02-18 | 中国医科大学 | 一种肿瘤靶向的新型多肽及其用途 |
| US20200061150A1 (en) | 2018-08-23 | 2020-02-27 | Nymox Corporation | Method of inducing selective prostate glandular pharmaco-ablation with sparing of nerves and preservation of sexual function |
| US11278588B2 (en) | 2019-05-13 | 2022-03-22 | Nymox Corporation | Method of treating lower urinary tract symptoms with fexapotide triflutate |
| US11298400B2 (en) | 2019-05-13 | 2022-04-12 | Nymox Corporation | Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS |
| US11331374B2 (en) | 2019-07-31 | 2022-05-17 | Nymox Corporation | Focal treatment of prostate cancer |
| US11231421B2 (en) | 2019-07-31 | 2022-01-25 | Nymox Corporation | Methods of treating multifocal cancer |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL93018C (enExample) * | 1957-10-22 | |||
| JPS5936174A (ja) * | 1982-08-23 | 1984-02-28 | Ricoh Co Ltd | インクジエツト記録用水性インク |
| JPS59106989A (ja) * | 1982-12-10 | 1984-06-20 | Ricoh Co Ltd | インクジエツト記録法 |
| US4588998A (en) * | 1983-07-27 | 1986-05-13 | Ricoh Company, Ltd. | Ink jet head having curved ink |
| US4994110A (en) * | 1986-08-27 | 1991-02-19 | Hewlett-Packard Company | Dyes containing lithium for ink-jet printing inks |
| US5231170A (en) * | 1986-08-27 | 1993-07-27 | Paul Averback | Antibodies to dense microspheres |
| US4874779A (en) * | 1988-06-29 | 1989-10-17 | Bristol-Myers Company | Mitomycin phosphate derivatives |
| US5948634A (en) * | 1988-12-21 | 1999-09-07 | The General Hospital Coporation | Neural thread protein gene expression and detection of alzheimer's disease |
| DE68927459T2 (de) * | 1988-12-21 | 1997-04-24 | Gen Hospital Corp | Nachweis einer neurologischen Krankheit oder einer Funktionsstörung |
| US5462592A (en) * | 1992-06-09 | 1995-10-31 | Ricoh Company, Ltd. | Aqueous ink composition |
| JP3176444B2 (ja) * | 1992-10-01 | 2001-06-18 | 株式会社リコー | 水性インク及びこれを用いた記録方法 |
| JP3247784B2 (ja) * | 1993-12-22 | 2002-01-21 | 株式会社リコー | 水性インク及びこれを用いた記録方法 |
| JP2888166B2 (ja) * | 1995-04-04 | 1999-05-10 | 富士ゼロックス株式会社 | インクジェット記録用インクおよびインクジェット記録方法 |
| JP3620097B2 (ja) * | 1995-04-28 | 2005-02-16 | 株式会社リコー | 水性インク |
| JP3350839B2 (ja) * | 1995-05-30 | 2002-11-25 | 株式会社リコー | インクジェット記録用イエローインク及び画像記録方法 |
| US5637138A (en) * | 1995-06-06 | 1997-06-10 | Brother Kogyo Kabushiki Kaisha | Ink composition, process for its preparation, and ink-jet recording process |
| JP3475249B2 (ja) * | 1996-07-25 | 2003-12-08 | 株式会社リコー | 記録液及びそれを用いた記録方法 |
| US5879439A (en) * | 1996-08-01 | 1999-03-09 | Ricoh Company, Ltd. | Recording ink composition and recording method using the same |
| US6620922B1 (en) * | 1997-02-25 | 2003-09-16 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| JP3583257B2 (ja) * | 1997-03-17 | 2004-11-04 | 株式会社リコー | 画像記録法及び画像記録装置並びに画像記録促進液 |
| US6120589A (en) * | 1998-02-20 | 2000-09-19 | Ricoh Company, Ltd. | Set of color ink compositions for ink-jet printing and method of forming color images using the color ink set |
| US6273985B1 (en) * | 1998-06-26 | 2001-08-14 | Xerox Corporation | Bonding process |
| US6613136B1 (en) * | 1999-09-17 | 2003-09-02 | Ricoh Company, Ltd. | Recording ink composition and ink-jet printing method using the same |
| CN1300778A (zh) * | 1999-12-22 | 2001-06-27 | 上海博德基因开发有限公司 | 一种新的多肽－人神经元线蛋白15和编码这种多肽的多核苷酸 |
| CN1300779A (zh) * | 1999-12-22 | 2001-06-27 | 上海博德基因开发有限公司 | 一种新的多肽－人神经元线蛋白17和编码这种多肽的多核苷酸 |
| US6730155B2 (en) * | 2000-06-30 | 2004-05-04 | Ricoh Company, Ltd. | Aqueous ink composition |
| JP3874336B2 (ja) * | 2000-12-05 | 2007-01-31 | 株式会社リコー | 記録液、これを用いたインクジェット記録方法及び記録用機器 |
| US6730149B2 (en) * | 2001-01-22 | 2004-05-04 | Ricoh Company Limited | Ink composition and inkjet recording method and apparatus using the ink composition |
| JP2002285047A (ja) * | 2001-03-23 | 2002-10-03 | Ricoh Co Ltd | 水性記録液、該液を用いた記録方法および機器 |
| WO2002097030A2 (en) * | 2001-05-25 | 2002-12-05 | Nymox Corporation | Peptides derived from neural thread proteins and their medical use |
| JP4587667B2 (ja) * | 2001-07-19 | 2010-11-24 | ナイモックス コーポレーション | 細胞の除去又は破壊を必要とする腫瘍及び他の状態の治療に有効なペプチド |
-
2002
- 2002-03-08 BR BR0207638-1A patent/BR0207638A/pt not_active IP Right Cessation
- 2002-03-08 CN CNA028062043A patent/CN1529613A/zh active Pending
- 2002-03-08 US US10/092,934 patent/US20030054990A1/en not_active Abandoned
- 2002-03-08 AU AU2002304314A patent/AU2002304314B2/en not_active Ceased
- 2002-03-08 AT AT02733095T patent/ATE374619T1/de active
- 2002-03-08 ES ES02733095T patent/ES2295347T3/es not_active Expired - Lifetime
- 2002-03-08 CA CA002439757A patent/CA2439757A1/en not_active Abandoned
- 2002-03-08 DK DK02733095T patent/DK1368054T3/da active
- 2002-03-08 JP JP2002573030A patent/JP2004529908A/ja active Pending
- 2002-03-08 EP EP02733095A patent/EP1368054B1/en not_active Expired - Lifetime
- 2002-03-08 DE DE60222745T patent/DE60222745T2/de not_active Expired - Lifetime
- 2002-03-08 KR KR1020037011672A patent/KR100632903B1/ko not_active Expired - Fee Related
- 2002-03-08 PT PT02733095T patent/PT1368054E/pt unknown
- 2002-03-08 WO PCT/IB2002/001959 patent/WO2002074323A2/en not_active Ceased
- 2002-03-08 EP EP07110879A patent/EP1857115A3/en not_active Withdrawn
-
2008
- 2008-01-02 CY CY20081100001T patent/CY1109650T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004529908A5 (enExample) | ||
| JP2005507647A5 (enExample) | ||
| JP2005506061A5 (enExample) | ||
| JP2004534533A5 (enExample) | ||
| JP2005521383A5 (enExample) | ||
| RU2269356C2 (ru) | Способ лечения онкологических заболеваний | |
| Paliwal et al. | Therapeutic opportunities in biological responses of ultrasound | |
| Weichselbaum et al. | Gene therapy targeted by ionizing radiation | |
| JP2012197294A (ja) | 癌治療感作物質 | |
| BG106028A (bg) | Имунотерапия на рак чрез експресия на скъсен туморен или тумор-асоцииран антиген | |
| JP6124791B2 (ja) | Ｓｍａｄ７の治療的適用 | |
| CN113795273A (zh) | 基于胶原肽的药物组合物和装置及其生产方法和用途 | |
| WO2002011747A2 (en) | Transglutaminase for inhibiting angiogenesis | |
| Prabhakar et al. | Gene therapy and its implications in dentistry | |
| JP2006518589A5 (enExample) | ||
| Kahalian et al. | Assessment of the methylene blue mediated photodynamic therapy on BCL2 and BAX genes expression at mRNA level and apoptosis of head and neck squamous cell carcinoma cell line | |
| O'Malley et al. | Somatic gene therapy in otolaryngology—head and neck surgery | |
| RU2105567C1 (ru) | Способ лечения злокачественных опухолей | |
| HS Shilpashree BDS et al. | Gene therapy in dentistry: a review | |
| RU2614665C1 (ru) | Способ стимуляции репаративного ангиогенеза и регенерации соединительной ткани, при её повреждении, методом генной терапии с использованием видоспецифичных генов белковых факторов vegf и fgf2, в ветеринарии, и генетическая конструкция для реализации заявленного способа | |
| US9669082B2 (en) | Proteinase-engineered cancer vaccine induces immune responses to prevent cancer and to systemically kill cancer cells | |
| De Giovanni et al. | The prospects for cancer gene therapy | |
| JP7246491B2 (ja) | 医薬組成物 | |
| CN118403154A (zh) | 一种抗癌药物组合物及其应用 | |
| SWAMY et al. | Gene Therapy Applications in Dentistry: A Review. |